Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings
CEO & Managing Director, Kate Munnings
Source: Virtus Health
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Virtus Health (VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the State Governments cope with the current COVID-19 outbreak
  • In NSW, all non-urgent elective surgeries have been suspended from January 10 but this does not apply to procedures where patients are admitted and dischared on the same day
  • The Victorian State Government has suspended all non-urgent elective surgeries from January 12 to April 12 with IVF treatment restricted to cycles beginning prior to January 6
  • Furthermore, Queensland has suspended all non-urgent elective surgeries in public hospitals, with only its services undertaken in private day hospitals unaffected
  • Virtus Health is up 0.3 per cent on the market with shares trading at $6.68 each

Virtus Health (VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the State Governments cope with the current COVID-19 outbreak.

In NSW, the State Government has suspended all non-urgent elective surgeries from January 10, 2022.

This suspension does not apply to procedures where patients are admitted and discharged on the same day. Therefore, this does not restrict IVF or other services provided by Virtus.

The Victorian State Government has suspended all non-urgent elective surgeries from January 12 until April 12, with IVF treatments restricted to cycles beginning prior to January 6.

If the Victorian direction continues for those three months, Virtus’ Victorian clinics will reduce its activity during this period with steps being taken to ease the impact of the reduced activity.

Meanwhile, Queensland has suspended all non-urgent elective surgeries in public hospitals only, therefore Virtus’ IVF and other services undertaken in private day hospitals are not affected.

Additionally, this current COVID-19 wave is presenting staff shortages, increased testing requirements and the deferral of procedures.

As a result of all these challenges, Virtus cannot accurately provide any near-term financial impacts. A further update will be made on February 15.

Virtus Health was down 0.3 per cent on the market with shares trading at $6.68 at 12:22 pm AEDT.

VRT by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX signs off on a sigh with all sectors red-lining

The ASX200 finished 1.3 per cent down with every sector in the red and Industrials and Real Estate brittle and bruised as bot…

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think…
The Market Online Video

Market Update: ASX on red alert with all sectors below the surface

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.